Articles tagged with Cancer Medication
The new NCCN Guidelines Navigator tool offers an interactive platform for accessing evidence-based guidelines, facilitating easier searching and navigation. The initiative aims to improve patient care and outcomes by providing healthcare professionals with up-to-date recommendations.
Two Purdue researchers received funding to advance university innovations. Andrew Mesecar aims to develop new treatments for hepatocellular carcinoma using patented enzyme inhibitors. Meanwhile, Pablo Zavattieri is working on a patent-pending system to address saltwater intrusion in the Panama Canal.
Researchers at the University of Pennsylvania School of Engineering and Applied Science have turned a deadly fungus into a potent cancer-fighting compound. The new compound, called asperigimycins, has shown promising results against leukemia cells, rivaling FDA-approved drugs.
The University of Texas Health Science Center at San Antonio is targeting hard-to-treat cancers and boosting HPV vaccination rates with a $3.4 million funding from CPRIT. The institution will expand its core facilities laboratories to increase researchers' ability to identify therapeutic targets and develop new cancer technologies.
A new study of 591 women with early-stage breast cancer found that nearly two-thirds opted for continued endocrine therapy beyond the initial five years. Patients with higher-risk stage 2 disease were more likely to continue treatment, highlighting potential benefits in extending hormone-based therapy for these patients.
Recent advances in tissue-agnostic cancer drugs have resulted in highly effective treatments, but few are approved for children. Oncologists argue that these drugs should be licensed for all ages due to their effectiveness and fewer side effects. The researchers suggest that age-agnostic approvals could be made through analyzing electr...
A new drug combination has shown significant improvements in overall survival for patients with advanced breast cancer who have the PIK3CA gene mutation. The treatment, which includes inavolisib, palbociclib, and fulvestrant, was found to extend median overall survival by 7 months compared to the placebo group.
The CompassHER2 trial found that neoadjuvant THP led to a pathologic complete response (pCR) rate of 64% in patients with early-stage HER2-positive, ER-negative breast cancer. Lower ER expression levels resulted in higher pCR rates among ER-positive tumors.
A phase 2 trial found that combining avelumab and cetuximab significantly extended median progression-free survival in patients with advanced cutaneous squamous cell carcinoma. The combination showed synergistic effects, suggesting a potential new standard of care for this patient population.
Researchers at VCU Massey Comprehensive Cancer Center have identified AEG-1 as the active regulator of inflammation responsible for chemotherapy-induced peripheral neuropathy (CIPN). Eliminating AEG-1 using targeted therapies could provide a critical strategy for managing CIPN in cancer patients.
Researchers at UCSF found that certain gut bacteria can reduce chemotherapy side effects by clearing excess drugs and producing the protective vitamin K2. Patients with more beneficial bacteria had fewer side effects, suggesting that probiotics may help mitigate chemotherapy's impact.
A new study at the University of Turku identified conditions under which Bexmarilimab activates the immune system against cancer. The drug was shown to trigger B cell-mediated immune responses in healthy tissue adjacent to tumors. This could lead to more accurate patient selection and improved treatment outcomes.
A research team from the University of Copenhagen has developed a biotechnological method to produce Taxol, a widely used cancer drug. The new method involves cloning taxol-producing genes and inserting them into yeast cells, making it more cost-effective and sustainable than traditional chemical synthesis.
UT Dallas bioengineers have created an enhanced light-activated immunotherapy approach to target advanced stomach cancer. Lab-designed molecules are primed with far-red or near-infrared light to activate the immune system against stubborn cancer cells, reducing side effects.
A new clinical trial has shown that a lower dose of radiotherapy can lead to higher levels of complete disappearance of cancer and fewer short-term side effects. The treatment approach, led by Professor David Sebag-Montefiore, aims to reduce the burden on patients and healthcare systems.
A real-world study of 1,752 patients with stage III or IV ovarian cancer found that adding bevacizumab to chemotherapy improved overall survival for those with advanced disease and residual cancer. Benefits were mostly seen in high-risk patients, not the general population.
Researchers discovered 500 cryptic peptides found only in pancreatic tumors, which could be targeted by vaccines or engineered T cells to attack the cancer. The peptides were identified using immunopeptidomics and shown to slow down tumor growth in mice.
Researchers at TUM developed an AI-powered algorithm to predict kidney damage in prostate cancer patients undergoing lutetium-177 PSMA therapy. Early detection could enable personalized treatment adjustments to prevent organ damage.
A Phase Ia/Ib trial found that zongertinib demonstrated clinical benefits for patients with advanced HER2-mutant non-small cell lung cancer, particularly those with specific HER2 mutations. The treatment showed a 71% objective response rate and manageable side effects.
A new voluntary program, the Medicare Prescription Payment Plan (MPPP), could greatly reduce out-of-pocket costs for Medicare patients taking expensive oral cancer drugs. By spreading annual costs across 12 monthly payments, patients can avoid large upfront payments and make treatment more affordable.
Researchers developed an AI platform that tracks cancer biomarkers to personalize treatment dose adjustments for patients with advanced solid tumors. The study resulted in optimal doses being administered to 97.2% of patients, with average reductions of 20%.
Researchers at Tulane University identified a potential new way to treat idiopathic pulmonary fibrosis (IPF) using an FDA-approved cancer drug. The treatment works by blocking the CTLA4 protein, which blocks overactive T cells, allowing the immune system to clear out damaged cells that cause lung scarring.
A UT Health San Antonio-led discovery could redefine drug discovery by turning IV medications into orally administered treatments for brain cancer, Alzheimer’s disease, and other complex conditions. The new strategy uses a protein receptor called CD36 to efficiently deliver large molecules into cells.
Researchers have discovered that pyrvinium pamoate, a common pinworm medication, can inhibit cancer cell growth and reverse neuroendocrine features in Merkel cell carcinoma. The medication also reduced tumor growth in mouse models of the disease.
Researchers at Duke University and colleagues discover a way to improve the uptake of cancer-fighting drugs called PROTACs by leveraging the CD36 protein. This approach delivered up to 23 times more potent treatment without compromising stability or solubility, paving the way for effective medications.
The University of Missouri is partnering with a consortium to design and license a new research reactor, NextGen MURR, which will produce critical medical isotopes for cancer treatment. The project aims to enhance Missouri's role as a leader in nuclear science and medical research.
Researchers at Keio University developed a method to grow millions of functional liver cells, revolutionizing drug testing and regenerative therapies. The breakthrough could lead to more effective treatments for liver diseases and accelerate the development of new organoids.
University of Virginia researcher Natasha D. Sheybani has received a $5.5 million grant to advance her research on focused ultrasound technology for breast cancer immunotherapy. Her work aims to enhance the safety, effectiveness, and precision of immunotherapy drugs.
Natasha Diba Sheybani, a UVA researcher, has received a $5.5 million grant to develop safer and more precise breast cancer treatments using focused ultrasound technology. Her work aims to overcome key bottlenecks in current treatments and improve patient outcomes.
A new study found that both employed people with obesity and employer representatives acknowledge the impact of obesity on future health problems and perceive lifestyle change alongside anti-obesity medications as the most effective approach for maintaining weight-loss reduction. Cost of medication coverage remains a significant barrie...
Researchers have developed drug-delivering aptamers that target and kill leukemia stem cells, reducing the need for high doses of chemotherapy. The aptamers pair well with existing drugs like daunorubicin to deliver a targeted one-two knockout punch against cancer.
A French research team has discovered that an organogold(III) complex accumulates selectively in the mitochondria of lung cancer cells, demonstrating its potential as an anticancer treatment. The complex's antitumor activity is attributed to its interactions with specific biological molecules, disrupting their function.
A novel AI-based method called scNET combines gene expression data with networks of possible gene interactions to identify biological patterns in response to drug treatments. The system reveals complex mechanisms underlying cellular behavior, providing insights for new therapeutic approaches.
A new study suggests that blood cancer patients receiving Bruton Tyrosine Kinase inhibitors should continue their therapy while getting vaccinated against COVID-19. The IMPROVE trial found no improvement in antibody responses when BTKi therapy was paused for three weeks around the time of vaccination.
A new study has found that a lower dose of the blood-thinning medication apixaban is as effective as the full dose in preventing recurring blood clots in patients with active cancer. Patients who received the lower dose experienced fewer bleeding complications and similar VTE recurrence rates compared to those on the standard dose.
A single-center retrospective study analyzed clinical data, imaging, histopathological manifestations, genetic testing results, and treatment effects in 48 WD patients. The study found age at diagnosis, K-F ring presence, and higher immunoglobulin G levels were associated with cirrhosis risk factors.
A multicentre study led from Finland has shown that lymph node transfer is a viable treatment for swelling in the affected limb after breast cancer surgery. The procedure involves transferring patient's lymph nodes to the armpit to replace removed lymph nodes, improving excess arm volume and reducing skin interstitial fluid.
Breast cancer survivors experience accelerated aging due to detrimental effects of BC and its treatments, particularly systemic therapies. The study highlights the need for ongoing monitoring and potential strategies to slow down aging in cancer survivors.
The WIN Consortium is transforming cancer care through personalized medicine, leveraging AI, molecular profiling, and clinical trials. The organization's innovations, including N-of-1 clinical trials and WINTHER and WINGPO trials, are helping clinicians make more precise treatment decisions and improving outcomes for cancer patients.
A new bacterial protein, BeeR, has been identified and its structure is being used to develop protein nanoparticles for targeted cancer drug delivery. The protein forms a hollow tube with a cavity capable of containing drug molecules.
Researchers at University of North Carolina Health Care found that combination immunotherapy before surgery increased survival rates in people with head and neck squamous cell carcinomas. The treatment regimen doubled or tripled the response rate versus single immunotherapy, leading to a survival benefit for up to a third of patients.
Researchers found that avapritinib decreases aggressive gliomas in animal models and in an initial cohort of patients with high-grade glioma. The drug targets the PDGFRA gene, which is commonly mutated in this type of cancer.
A team of researchers from Chiba University has developed a novel radioactive drug that targets and treats metastatic melanoma. The treatment utilizes astatine-211 labeled peptide analog, which shows high accumulation in tumors, rapid clearance from non-target organs, and significant tumor suppression.
Researchers found that pancreatic cancer cells gain a survival edge by carrying copies of critical cancer genes on circular pieces of DNA outside chromosomes. The discovery highlights the importance of targeting extrachromosomal DNA in treating the disease.
Researchers at Waseda University develop a new imaging technique that uses neutron activation to transform gold nanoparticles into radioisotopes, enabling long-term tracking of their movement in the body. This breakthrough could lead to more effective cancer treatments and precision monitoring of drug distribution.
Researchers used CRISPR to cut a single gene from cancer cells of head and neck tumors, resulting in the elimination of 50% of the tumors after 84 days. This groundbreaking study demonstrates that some genes are essential for cancer cell survival, making them excellent targets for CRISPR therapy.
Researchers found that aspirin prevents cancers from spreading by decreasing a clotting factor called thromboxane A2 and releasing T cells from suppression. This discovery could lead to the development of targeted treatments to prevent cancer metastasis, making aspirin potentially less expensive than antibody-based therapies.
A new study published in the European Journal of Preventive Cardiology found that a type of diabetes medication called SGLT2 inhibitors can significantly lower the risk of heart failure and hospital visits related to heart failure in cancer patients. The benefits were particularly promising for breast cancer patients receiving anthracy...
Researchers at UTEP secured a patent for anti-malarial drug pyronaridine, which slows cancer cell growth and induces programmed cell death, sparing healthy cells.
A new study found that nearly 20% of cancer patients in middle-stage drug trials receive treatment that later gets FDA approval. This has important implications for drug development and clinical trial recruitment.
Professor Collen Masimirembwa receives Precision Medicine World Conference Pioneer Award for his groundbreaking work in pharmacogenomics, advancing personalised medicine and tailoring treatments to individual genetic profiles. His research has improved patient outcomes and saved lives by uncovering critical issues with HIV medications.
Researchers at Pusan National University have developed a novel drug delivery system that uses nanoparticles to target and kill colorectal cancer cells. The system, which involves encapsulating cancer cell-activated nanoconjugates in an alginate matrix, can selectively deliver drugs to tumor cells while minimizing side effects.
ABT-263 eliminates harmful aging cells in the gut, reducing inflammation and lowering cancer risk in a mouse model of GI cancer. The study suggests that removing senescent cells could help prevent radiation-related GI cancer, highlighting the potential of senolytic drugs as a preventive treatment.
Researchers discover mitochondrial transfer between cancer cells and immune cells as a key immune evasion strategy. Cancer cells can reshape the tumor microenvironment to weaken tumor-infiltrating lymphocytes, and mitochondria play a significant role in this process.
A new 3D bioprinted gastric cancer model successfully replicates the unique characteristics of individual patients' tissues, predicting drug responses and prognosis with high accuracy. This innovative platform enables rapid evaluation within two weeks, contributing to personalized cancer treatment development.
A new genetic mutation, RUFY1-RET fusion, was discovered in a patient with stage IV CD-74-ROS1 fusion NSCLC who developed resistance to lorlatinib. The finding highlights the importance of ongoing genetic testing to guide therapy decisions.
A new tool named retriever extracts disease-specific drug response signatures to predict cancer treatment combinations, improving personalized treatment strategies. The tool refines predictions using single-cell RNA sequencing data and demonstrates its potential in identifying effective treatments for triple-negative breast cancer.
Researchers at the CNIC have designed a treatment strategy to protect the heart against cardiotoxic effects of anthracyclines, a common class of anticancer drugs. Empagliflozin, an SGLT2 inhibitor, has been shown to preserve cardiac function and metabolism in experimental models.
The team's novel technique enables high-throughput screening of nanoparticle shapes, sizes, and modifications, reducing associated screening costs. The research demonstrates the distinct preferences of tumour cells for certain nanoparticle configurations, enabling personalized cancer treatments that are safer and more effective.
A new study published in Nature Medicine shows a promising approach to preventing metastases in breast cancer patients. Researchers found that administering digoxin reduced circulating tumour cell clusters by an average of 2.2 cells, significantly decreasing the risk of metastasis.